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THE USE OF MULTI-ATTRIBUTE ANALYSIS AND 
PAIR-WISE COMPARISONS FOR GROUP 
DECISION-MAKING
Hess GP1, Forman E2
1CareScience, Philadelphia, PA, USA; 2George Washington 
University, Washington, DC, USA
OBJECTIVES: Decision-making is a process of assessing
alternatives and their attributes versus an objective(s),
trading-off various advantages and disadvantages, and
ultimately synthesizing the information to culminate at a
central point: a decision. The aim of the workshop is to
outline a systematic process for group decision-making.
A formulary decision incorporating clinical, economic
and humanistic data from the perspective of a hospital
committee will be used as an illustration.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who are involved in creating group decision-analytic
models and systems, and stakeholders involved in formu-
lary selection.
A key issue in pharmaceutical research is the development
and use of applied approaches to help decision-makers
synthesize various pieces of information and arrive at a
decision. Decision-making is often difficult because trade-
offs must be made among competing objectives and pri-
orities. In order to make tradeoffs, we must be able to
evaluate and measure each aspect of the decision—some
quantitative, some qualitative, some very important, and
some not so important. Uncertainties and competing in-
terest groups also add to the complexity of decision-mak-
ing. The ability to make effective decisions in the face of
complexity can be significantly increased by a systematic
process incorporating multiple attributes (economics, clin-
ical outcomes, etc.) and pairwise comparisons (A vs. B, B
vs. C, A vs. C). The session will describe a systematic ap-
proach and provide an interactive illustration for con-
struction of a decision-model based on a process devel-
oped by mathematicians at the Wharton School of the
University of Pennsylvania. A model will be developed
for the formulary selection of cholesterol lowering statins
from a hospital P&T perspective, considering economic,
clinical and humanistic outcomes, with participation
from the audience including handheld key pads for input.
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MULTINATIONAL ECONOMIC STUDIES: 
LESSONS LEARNED FROM TRIAL-BASED AND 
MODELLING STUDIES
Drummond MF1, Grima D2
1University of York, Heslington, York, UK; 2Innovus Research 
Inc, Burlington, ON, Canada
WORKSHOP OBJECTIVE: The interest in multinational
health economic studies has grown with the number of
countries requiring economic data on new pharmaceuti-
cals. The workshop will explore and illustrate challenges
in the conduct of international studies using examples
from the presenters’ research while providing an oppor-
tunity for participants to share their experiences.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who are involved in the design, execution or commis-
sion of multinational health economic studies.
As health care expenditures have risen, so too has scrutiny
over the economic value of new pharmacological inter-
ventions. Many countries now require that the cost-
effectiveness of new agents be addressed in formal analy-
ses as part of the regulatory approval process. Given
these widespread requirements, there has been a growing
interest in undertaking multinational health economic
studies that can be used as the basis for submissions in
multiple countries. Two main strategies to provide health
economic data include: creation of decision analytic mod-
els that utilize existing clinical, epidemiological and cost
data, and collection of economic data alongside multina-
tional clinical trials. Each raises methodological chal-
lenges, which will be discussed using examples from stud-
ies in rheumatology, vaccination, stroke, and cardiovascular
disease. For example, in modeling studies, how does one
accommodate local clinical practice patterns? In trial-
based studies, how does one decide whether economic
data can be pooled or not? Multinational studies also
raise a number of practical issues, such as the involve-
ment of a cross-section of international experts to avoid
the introduction of country-specific biases, creation of
buy-in among national offices and decision experts, avail-
ability of resource use and unit cost data, and require-
ments for a multinational publication strategy. These is-
sues will also be discussed.
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USING MARKOV DECISION MODELS TO 
DEVELOP OPTIMAL TREATMENT PATHWAYS: 
AN ILLUSTRATION
Bala MV1, Mauskopf JA2
1Centocor, Inc, Malvern, PA, USA; 2Research Triangle Institute, 
Research Triangle Park, NC, USA
OBJECTIVES: The objective of this workshop will be to
develop skills in the use of Markov decision models to
develop treatment pathways that are optimal from a
pharmacoeconomic perspective.
PARTICIPANTS WHO WOULD BENEFIT: Analysts or
decision-makers involved in the conduct or evaluation of
pharmacoeconomic studies.
Cost-effectiveness analysis of an intervention for a
chronic condition requires estimates of cost and efficacy
over the rest of the patient’s life time. However efficacy
estimates are commonly derived from clinical trials with
limited duration of follow-up. This creates the need for
modeling to estimate cost and efficacy beyond the follow-
up period. Markov modeling is the most commonly used
modeling technique to perform this estimation. However,
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as commonly applied, Markov models are used to deter-
mine if the new intervention is cost-effective if used in-
stead an old one at one point in the patient’s lifetime.
These models do not attempt to determine the lifetime
optimal treatment pathway for treating the disease. We
show how Markov decision models can be used to de-
velop an optimal treatment pathway, by assigning a
treatment option to each health state so as to maximize
overall net benefit. We will demonstrate how to derive
the optimal treatment pathway using dynamic program-
ming. We will present an illustrative example of the use
Markov decision model for a chronic disease such as
HIV. We will discuss some potential ethical issues that
could be raised by the optimal policies derived from
Markov decision models. We will conclude the workshop
with an interactive discussion of the benefits and draw-
backs of Markov decision models.
WW12
USE OF MEDICATION COMPLIANCE DATA IN 
OUTCOME ANALYSES
Cramer JA1, Urquhart J2,3
1Yale University School of Medicine, West Haven, CT, USA; 
2Maastricht University, Maastricht, The Netherlands; 3AARDEX 
Ltd., Zug, Switzerland
OBJECTIVES: Participants will learn how to collect, an-
alyze, and use compliance data to perform per protocol
analyses that can demonstrate effectiveness and shape
models based on treatment persistence. Examples will in-
clude effectiveness for alcoholism, AIDS, cardiovascular
and mental illnesses.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who evaluate treatment outcomes, pharmacoeco-
nomic specialists who evaluate treatment costs, and other
health outcomes professionals.
Many people are negligent “partial compliers” who miss
doses regularly or intermittently despite the best inten-
tions and an understanding of the importance of taking
medication. In addition, long-term persistence with chronic
treatments is poor. These two manifestations of poor
compliance, confound assessment of drug effects, result
in poor quality medical care, and affect the overall cost of
care. Poorly compliant patients, because of their non-
response to drug treatment, advance to the uppermost
steps of stepped-care schemes, incurring needless diag-
nostic costs and treatment costs. The clinical and eco-
nomic consequences of poor compliance can range from
trivial to catastrophic, depending upon drug, disease and
its severity, and co-morbidities. Actual dose-taking and
dose-timing data collected from individuals can be linked
to efficacy parameters to stratify treatment effectiveness
based on compliance. The importance of using real-time
compliance data in outcomes analyses will be described
with examples from electronic compliance techniques.
Examples will include use of compliance data to demon-
strate value to patients and providers, as well as the phar-
maceutical industry.
WW13
CHALLENGES IN PERFORMING META ANALYSIS 
IN HEART FAILURE OUTCOMES RESEARCH
Mullins CD1, Weiss S1, Fulda T2
1University of Maryland, Baltimore, MD, USA; 2U.S. 
Pharmacopeia, Rockville, MD, USA
OBJECTIVES: Incorporating additional information
from the outcomes research literature (i.e. pharmacoeco-
nomics, pharmacoepidemiology, and quality of life) into
drug information resources used by clinical practitioners
presents a unique challenge. The objective of this work-
shop is to describe the complex issues involved when pro-
viding outcomes research information to clinicians who
are involved in drug therapy selection. Based on the expe-
riences of the presenters, cautionary statements about
meta analysis in outcomes research, with application to
heart failure, will be provided.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers interested in the epidemiologic, economic, and quality
of life aspects of heart failure, as well as those interested
in meta analysis and comparability of studies for clinical
practice and decision-making.
The practical applicability of outcomes research for clini-
cians represents a significant challenge. Drug information
sources could assist in making outcomes research find-
ings both succinct and “user friendly” if there were suffi-
cient literature and a means for compiling the salient
findings. The medical and pharmacy literature has an
abundant amount of information on heart failure and re-
lated treatments. Thus, it would appear that outcomes re-
search in heart failure could serve as a test case for pro-
ducing practical guidance for clinicians; however, a
number of general issues need to be addressed. How
should one objectively determine inclusion/exclusion cri-
teria for research studies? When should meta analysis be
performed and on what outcomes? When should findings
be reported for drug classes rather than individual
agents? There are also a number of questions that are
specific to heart failure. How and to what extent should
the severity of patients be used to group or stratify find-
ings? How should data on comorbidites be incorporated?
These questions will be explored in general and as part of
a heart failure case study.
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MAKING MODELS BETTER
Matchar DB1, Samsa GP1, Parmigiani G2
1Duke University, Durham, NC, USA; 2Johns Hopkins School of 
Medicine, Baltimore, MD, USA
